| ISIN | LU1047627192 |
|---|---|
| Valor Number | 23949332 |
| Bloomberg Global ID | |
| Fund Name | Crossfund Sicav-Crossinvest Swiss Opportunity Fund B-CHF |
| Fund Provider |
Crossinvest SA
Lugano, Switzerland Phone: +41 91 911 88 88 E-Mail: info@crossinvest.ch Web: www.crossinvest.ch |
| Fund Provider | Crossinvest SA |
| Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
| Distributor(s) |
FundPartner Solutions (Suisse) SA Genève 3 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
| Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
| Investment Strategy *** | The investment objective of the Sub-Fund is to achieve a long term capital growth in Swiss Francs by pursuing exposure opportunities to the Swiss market. The Sub-Fund is actively managed. The Sub-Fund has no benchmark index and is not managed in reference to a benchmark index. |
| Peculiarities |
| Current Price * | 138.66 CHF | 16.01.2026 |
|---|---|---|
| Previous Price * | 139.34 CHF | 15.01.2026 |
| 52 Week High * | 139.34 CHF | 15.01.2026 |
| 52 Week Low * | 115.88 CHF | 09.04.2025 |
| NAV * | 138.66 CHF | 16.01.2026 |
| Issue Price * | 138.66 CHF | 16.01.2026 |
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 41,669,941 | |
| Unit/Share Assets *** | 238,440 | |
| Trading Information SIX | ||
| YTD Performance | +1.43% |
31.12.2025 - 16.01.2026
31.12.2025 16.01.2026 |
|---|---|---|
| 1 month | +3.19% |
16.12.2025 - 16.01.2026
16.12.2025 16.01.2026 |
| 3 months | +5.44% |
16.10.2025 - 16.01.2026
16.10.2025 16.01.2026 |
| 6 months | +9.77% |
16.07.2025 - 16.01.2026
16.07.2025 16.01.2026 |
| 1 year | +9.81% |
16.01.2025 - 16.01.2026
16.01.2025 16.01.2026 |
| 2 years | +19.80% |
16.01.2024 - 16.01.2026
16.01.2024 16.01.2026 |
| 3 years | +17.46% |
16.01.2023 - 16.01.2026
16.01.2023 16.01.2026 |
| 5 years | +14.11% |
18.01.2021 - 16.01.2026
18.01.2021 16.01.2026 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Novartis AG Registered Shares | 9.84% | |
|---|---|---|
| Roche Holding AG | 9.35% | |
| Nestle SA | 7.32% | |
| Compagnie Financiere Richemont SA Class A | 6.64% | |
| UBS Group AG Registered Shares | 6.43% | |
| ABB Ltd | 4.94% | |
| Zurich Insurance Group AG | 4.75% | |
| Holcim Ltd | 4.57% | |
| Swiss Re AG | 3.59% | |
| Swiss Life Holding AG | 3.52% | |
| Last data update | 30.09.2025 | |
| TER *** | 2.262% |
|---|---|
| TER date *** | 30.11.2025 |
| Performance Fee *** | 10.00% |
| PTR | |
| Max. Management Fee *** | 1.70% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| SRRI date *** | 31.12.2025 |